Table 1.
Clinical characteristics.
| Case No. | Age (yr) | Previous GYN History | Presenting Symptom | MRI Finding | CA 125 (U/mL) | CA 19-9 (U/mL) | Surgery | Post-Operative Treatment | Post-Operative Local Recurrence | Post-Operative Distant Metastasis | DFS (mo) | Current Status | Alive/ Dead | OS (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 54 | HRT | An EM mass detected on US during routine follow-up | A 2.9 cm linear EM lesion; no peritoneal seeding; no lymph node metastasis; no distant metastasis (MRI FIGO stage IA) | 5.2 | NA | TH + BSO + PLND | None | Absent | Absent | 15 | NED | Alive | 18 |
| 2 | 68 | None | Vaginal bleeding | A 3.3 cm EM mass with small separate lesions; no peritoneal seeding; no lymph node metastasis; no distant metastasis (MRI FIGO stage IA) | 5.3 | NA | TH + BSO + PLND | None | Absent | Absent | 6 | NED | Alive | 9 |
| 3 | 57 | None | Vaginal bleeding | A 5.1 cm EM mass; no peritoneal seeding; no lymph node metastasis; no distant metastasis (MRI FIGO stage IA) | 29.5 | NA | TH + BSO + PLND | VBT (ongoing) | NA | NA | NA | NA | NA | NA |
| 4 | 67 | Recurrent tamoxifen-related EM polyp | EM and adnexal masses detected on US during routine follow-up | A 4.5 cm EM mass; a 4.4 cm enhancing lobulating ovarian mass; no peritoneal seeding; no lymph node metastasis; no distant metastasis (MRI FIGO stage IIIA) | 134.7 | NA | TH + BSO + PLND + PALND | Whole pelvic RT | Absent | Absent | 13 | NED | Alive | 16 |
| 5 | 56 | None | Vaginal bleeding | A 8.8 cm EM mass with cervical extension and suspected focal serosal extension; no peritoneal seeding; no lymph node metastasis; no distant metastasis (MRI FIGO stage IIIA) | 143.2 | 468.0 | TH + BSO + PLND + PALND | CCRT (ongoing) | NA | NA | NA | NA | NA | NA |
Abbreviations: GYN, gynecological; MRI, magnetic resonance imaging; HRT, hormone replacement therapy; EM, endometrium; US, ultrasonography; NA, not applicable; TH, total hysterectomy; BSO, bilateral salpingo-oophorectomy; PLND, pelvic lymph node dissection; NED, no evidence of disease; VBT, vaginal brachytherapy; PALND, para-aortic lymph node dissection; RT, radiation therapy; CCRT, concurrent chemoradiation therapy; DFS, disease-free survival; OS, overall survival.